Concepedia
Statistics
Publications
4
Citations
99
H-Index
Active since
2019
Affiliations
Institute of Group Analysis(Current)
Analysis Group (United States)
Merck & Co., Inc., Rahway, NJ, USA (United States)
MSD (Netherlands)
Madeline Jenkins is an author at Institute of Group Analysis specializing in cost-effectiveness analysis, pharmacy, and oncology.
Publications per year
2019–2025
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration
Nathalie Goemans, Brenda Wong, M. van den Hauwe et al. · PLoS ONE · 2020 · 36 citations · Full text
Medicine, Biostatistics, Pharmacotherapy +16
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Arielle G. Bensimon, Zheng‐Yi Zhou, Madeline Jenkins et al. · Journal of Medical Economics · 2019 · 30 citations · Full text
Pharmacy, Oncology, Pharmacoeconomics +17
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
Arielle G. Bensimon, Zheng‐Yi Zhou, Madeline Jenkins et al. · Clinical Drug Investigation · 2020 · 22 citations · Full text
PET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker of Neuroinflammation
Yan Xuefeng, Cheryl L. Morse, Jeih‐San Liow et al. · Journal of Nuclear Medicine · 2025 · 11 citations · Full text
Life Sciences, Neurobiology, Neuroscience +13
1–4 of 4